Contact Our Partner Laboratory
Formerly Racoo Screening Ltd, 258 POSTAL RACOO SCREENING LTD has over 15 years experience in the implementation of workplace Drug and Alcohol testing programmes, DNA and Infectious Disease screening. We deliver a complete and fully managed service to commercial organisations, professional and amateur sport, local authorities and the public sector.
We possess unrivalled experience and are fully committed to providing a quality, professional yet flexible service to our Clients; engaging fully with their Management Teams and staff members.
Our Drug and Alcohol, DNA and Infectious disease testing services are fully accredited and conform to industry best practice. We have over 20 years’ experience in the industry which allows us to meet each Client’s needs in an individual and personal way.
Our Partner Laboratory
258 POSTAL RACOO SCREENING LTD has selected Randox laboratories to be its preferred laboratory partner. The unique drop box network of Randox makes it a market leader in fast turn around results.
258 Postal Testing can provide PCR Tests for Travel, Fit to Fly, Test to Release, Day 2, Day 8, Arrivals Test Packages and Pre Event Testing.
The Randox COVID-19 test underwent evaluation within, and was accepted by, Public Health England.
In its evaluation of the Randox COVID-19 test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.
Randox have almost 40 years of experience as a primary manufacturer in the IVD (in vitro diagnostics) industry. Last year we manufactured over 3 billion tests and exported to 145 countries. Randox are an ISO 13485 accredited manufacturer of in-vitro diagnostic medical devices, are a provider of a global laboratory accreditation scheme (RIQAS) accredited to ISO 17043, and run a number of ISO 17025 accredited laboratories. As an exporter to 145 countries and a manufacturer to other diagnostic companies we undergo multiple external audits each year, in order to remain engaged with our global markets.
At the time of the emergence of the COVID-19 threat, Randox had already developed seven CE marked assays for a range of viruses, including a number of other coronaviruses.
Upon identifying the latest strain of coronavirus as a significant global threat, Randox was able to harness our R&D capability, and some 40 years’ in diagnostics, including viral tests, to develop an effective COVID-19 assay with the same rigorous validation processes that we applied to all our other assays.